MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
Effective January 20, 2026, MBX Biosciences appointed Laurie Stelzer as an independent director and chairperson of the Audit Committee, replacing Ed Mathers.
Stelzer also joins the Compensation Committee; other committees unchanged.
She is designated as a Class I director serving until the 2028 annual meeting.
Board size increased to eight directors, filling an existing vacancy.
Stelzer has extensive experience as CFO at companies like Kailera Therapeutics, Orna Therapeutics, Mirati Therapeutics, and others, plus board roles at Sionna, PMV, and Spyre Therapeutics.
Company issued press release on January 22, 2026, and filed 8-K with SEC.